Recent Material Events - Vion Pharmaceuticals (VION)

Filing Date	Description
2008-09-23	On September 22, 2008, Vion Pharmaceuticals, Inc. announced that it had entered into an agreement with the Institut Paoli- Calmettes in Marseille, France to conduct a multi-center Phase I/II clinical trial of laromustine (Cloretazine ® (VNP40101 ...
2008-08-21	On August 19, 2008, Vion Pharmaceuticals, Inc. announced that it had entered into an agreement with the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) to conduct a clinical trial of laromustine (Cloretazine® (VNP40101M)) w ...
2008-08-18	On August 14, 2008, Vion Pharmaceuticals, Inc. (the “Company”) , announced that the Company had received a letter from NASDAQ on August 13, 2008 informing the Company that it would be delisted from the Nasdaq Stock Market and trading in its ...
2008-07-18	On July 17, 2008, Vion Pharmaceuticals, Inc. (the “Company”) announced to its employees that it had adopted a bonus and retention plan (the “Plan”) covering each Company employee, including the named executive officers. Under the ...
2008-06-30	On June 25, 2008, Aileen Ryan, the Vice President, Regulatory Affairs of Vion Pharmaceuticals, Inc. (the “Company”), advised the Company of her intent to resign effective July 11, 2008. ...
2008-06-04	On June 2, 2008, Vion Pharmaceuticals, Inc. issued a press release announcing that it had presented interim data from the pivotal Phase II trial of its lead anticancer agent Cloretazine® (VNP40101M) in elderly patients with de novo poor-risk acu ...
2008-05-09	On May 8 2008, Vion Pharmaceuticals, Inc. (the “Company”) held a teleconference to discuss its financial results for its first quarter ended March 30, 2008. A transcript of this teleconference is attached as Exhibit 99.1 to this Current Rep ...
2008-05-06	On May 5, 2008, Vion Pharmaceuticals, Inc. (the “Registrant”) issued a press release reporting its financial results for the three-month period ended March 31, 2008. ...
2008-03-28	On March 24 2008, Meghan Fitzgerald, the Vice President and Chief Business Officer of Vion Pharmaceuticals, Inc. (the “Company”), advised the Company of her intent to resign effective April 4, 2008. ...
2008-03-26	On March 24, 2008, Vion Pharmaceuticals, Inc. (the “Company”) received written notification (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”) that the Company fails to comply with the minimum stockholders’ equi ...